Burtrum, Douglas Bryan,Shen, Juqun,Wang, Cheng,Ludwig, Dale Lincoln
申请号：
NZ74915917
公开号：
NZ749159A
申请日:
2017.07.20
申请国别(地区):
NZ
年份:
2020
代理人:
摘要：
The present disclosure relates to an antibody that binds to canine platelet derived growth factor receptor (PDGFR) alpha. The antibody is derived and adapted from Olaratumab, a human PDGFR antibody, that has been developed for the treatment of solid tumours. The 6 CDRs of the antibody are as follows； HCDR1: TVSGGSIQSSSYYWG, HCDR2: SFFYTGSTYYNPSLRS, HCDR3: ARQSTYYDGSGNYYGWFDR, LCDR1: RASQAVSSYLA, LCDR2: YDASNRAT, LCDR3: QQRSNWPPA. The claimed antibody is indicated for use in the treatment of osteosarcoma or for treating a disease or condition associated with an overexpression of PDGFR in canines.
